Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

avet health limited - ampicillin as the sodium salt; cloxacillin as the sodium salt - misc. intra mammary - ampicillin as the sodium salt antibiotic active 75.0 mg/3gsy; cloxacillin as the sodium salt antibiotic active 200.0 mg/3gsy - antibiotic & related - cattle lactating | bovine - corynebacterium pyogenes | escherichia coli (e. coli) | staphylococci | streptococci | including b-lactamase producin

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

avet health limited - ampicillin as the sodium salt; cloxacillin as the sodium salt - misc. intra mammary - ampicillin as the sodium salt antibiotic active 75.0 mg/3gsy; cloxacillin as the sodium salt antibiotic active 200.0 mg/3gsy - antibiotic & related - cattle | beef | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | heifer | steer - mastitis | subclinical mastitis

United States - English - NLM (National Library of Medicine)

general injectables & vaccines, inc - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd) - ampicillin 500 mg in 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin and other antibacterial drugs, ampicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ampicillin is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: respiratory tract infections caused by s. pneumoniae (formerly d. pneumoniae), staphylococcus aureus (penicillinase and non-penicillinase producing), h. influenzae and group a beta-hemolytic streptococci. bacterial meningitis caused by e. coli, group b streptococci, and other gram-negative bacteria (listeria monocytogenes, n. meningitidis).

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

norbrook laboratories australia pty limited - ampicillin as the sodium salt; cloxacillin as sodium monohydrate salt - misc. intra mammary - ampicillin as the sodium salt antibiotic active 75.0 mg/5gsyr; cloxacillin as sodium monohydrate salt antibiotic active 200.0 mg/5gsyr - antibiotic & related - dairy cattle lactating | bovine | milking cow - antibiotic - anti-infective | antibiotics - oral, parenteral | arcanobacterium spp. | bacterial infection | corynebacterium spp. | escherichia coli (e. coli) | mastitis | organisms sensitive to cloxacillin | staphylococcus spp. | streptococcus agalactiae | streptococcus spp. | abrasions | abscesses | airsacculitis | amoxycillin sensitive bacteria | anaerobic bacterial infection | antiseptic | associated with viral disease | avian mycoplasmas | bacterial canker | blackhead | body odours | bowed tendons | broad spectrum | burns | clavulanic acid sensitive | coccidiosis | coliform complex | conjunctivitis | coryza | cowpox | cracks | crd | crusts | dandruff | dermatological disorders | dermatoses | dermatosis | diarrhoea | dry skin | dysentery | eczema | endometritis | enteric diseases | enteritis | enzootic pneumonia | escherichia coli | european brood disease | feed efficiency | fungal infections | gentamicin sensitive | girth galls | gram negative organisms | gram positive organisms | hypermotility | includin

United States - English - NLM (National Library of Medicine)

wg critical care, llc - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd) - ampicillin 250 mg - ampicillin for injection, usp is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: respiratory tract infections caused by s. pneumoniae, staphylococcus aureus (penicillinase and non-penicillinase producing), h. influenzae and group a beta-hemolytic streptococci. bacterial meningitis caused by e. coli, group b streptococci, and other gram-negative bacteria (listeria monocytogenes, n. meningitidis ). the addition of an aminoglycoside with ampicillin may increase its effectiveness against gram-negative bacteria. septicemia and endocarditis caused by susceptible gram-positive organisms including streptococcus spp., penicillin-g-susceptible staphylococci and enterococci. gram-negative sepsis caused by e. coli, proteus mirabilis and salmonella spp. responds to ampicillin. endocarditis due to enterococcal strains usually respond to intravenous therapy. the addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. urinary tract infections caused by sensitive strains of e. coli and proteus mirabilis . gastrointestinal infections caused by salmonella typhi (typhoid fever), other salmonella spp. and shigella spp. (dysentery) usually respond to oral or intravenous therapy. bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. therapy may be instituted prior to obtaining results of susceptibility testing. it is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. a change to oral ampicillin may be made as soon as appropriate. indicated surgical procedures should be performed. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection, usp and other antibacterial drugs, ampicillin for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. a history of a previous hypersensitivity reaction to any of the penicillins is a contraindication.

United States - English - NLM (National Library of Medicine)

claris life sciences inc. - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd), sulbactam sodium (unii: dkq4t82ye6) (sulbactam - unii:s4tf6i2330) - ampicillin 1 g - ampicillin and sulbactam for injection, usp is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. skin and skin structure infections caused by beta-lactamase producing strains of staphylococcus aureus, escherichia coli,2 klebsiella spp.2 (including k. pneumoniae2 ), proteus mirabilis,2 bacteroides fragilis,2 enterobacter spp.,2 and acinetobacter calcoaceticus.2 note: for information on use in pediatric patients see precautions – pediatric use and clinical studies sections.  intra-abdominal infections caused by beta-lactamase producing strains of escherichia coli, klebsiella spp. (including k. pneumoniae2 ), bacteroides spp. (including b. fragilis ), and enterobacter spp.2 gynecological infections caused by beta-lactamase producing strains of escherichia coli,2  and bacteroides spp.2 (including b. fragilis2 ). __________ 2 efficacy for this microorganism in this organ system was studied in fewer than 10 infec

United States - English - NLM (National Library of Medicine)

sandoz inc - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd), sulbactam sodium (unii: dkq4t82ye6) (sulbactam - unii:s4tf6i2330) - ampicillin 1 g - ampicillin and sulbactam for injection is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. skin and skin structure infections caused by beta-lactamase producing strains of staphylococcus aureus, escherichia coli*, klebsiella spp.* (including k. pneumoniae* ), proteus mirabilis*, bacteroides fragilis*, enterobacter spp. *, and acinetobacter calcoaceticus*. note: for information on use in pediatric patients (see precautions - pediatric use and clinical studies sections). intra-abdominal infections caused by beta-lactamase producing strains of escherichia coli, klebsiella spp. (including k. pneumoniae*) , bacteroides spp. (including b. fragilis ), and enterobacter spp.* gynecological infections caused by beta-lactamase producing strains of escherichia coli*, and bacteroides spp.* (including b. fragilis* ). *efficacy for this organism in this organ system was studied in fewer than 10 infections. while ampicillin and s

United States - English - NLM (National Library of Medicine)

hospira, inc - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd), sulbactam sodium (unii: dkq4t82ye6) (sulbactam - unii:s4tf6i2330) - ampicillin 1 g - ampicillin and sulbactam for injection is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. skin and skin structure infections caused by beta-lactamase producing strains of staphylococcus aureus, escherichia coli*, klebsiella spp.* (including k. pneumoniae* ), proteus mirabilis*, bacteroides fragilis*, enterobacter spp. *, and acinetobacter calcoaceticus*. note: for information on use in pediatric patients (see precautions - pediatric use and clinical studies sections). intra-abdominal infections caused by beta-lactamase producing strains of escherichia coli, klebsiella spp. (including k. pneumoniae* ), bacteroides spp. (including b. fragilis ), and enterobacter spp.* gynecological infections caused by beta-lactamase producing strains of escherichia coli*, and bacteroides spp.* (including b. fragilis* ). * efficacy for this organism in this organ system was studied in fewer than 10 infections. while ampicillin and

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd), sulbactam sodium (unii: dkq4t82ye6) (sulbactam - unii:s4tf6i2330) - ampicillin 1 g in 1.5 g - ampicillin and sulbactam for injection, usp is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. skin and skin structure infections caused by beta-lactamase producing strains of staphylococcus aureus, escherichia coli* , klebsiella spp.* (including k. pneumoniae *), proteus mirabilis *, bacteroides fragilis *, enterobacter spp.*, and acinetobacter calcoaceticus *. note: for information on use in pediatric patients see precautions-pediatric use and clinical studies sections. intra-abdominal infections caused by beta-lactamase producing strains of escherichia coli, klebsiella spp. (including k. pneumoniae *), bacteroides spp. (including b. fragilis ), and enterobacter spp.* gynecological infections caused by beta-lactamase producing strains of escherichia coli *,  and bacteroides spp.* (including b. fragilis *). *efficacy for this organism in this organ system was studied in fewer than 10 infections. while ampicillin

United States - English - NLM (National Library of Medicine)

wg critical care, llc - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd), sulbactam sodium (unii: dkq4t82ye6) (sulbactam - unii:s4tf6i2330) - ampicillin 1 g in 20 ml - ampicillin and sulbactam for injection, usp is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. skin and skin structure infections caused by beta-lactamase producing strains of staphylococcus aureus, escherichia coli * , klebsiella spp.* (including k. pneumoniae * ), proteus mirabilis * , bacteroides fragilis * , enterobacter spp.* , and acinetobacter calcoaceticus * . note: for information on use in pediatric patients see precautions, pediatric use and clinical studies sections. intra-abdominal infections caused by beta-lactamase producing strains of escherichia coli, klebsiella spp. (including k. pneumoniae * ), bacteroides spp. (including b. fragilis ), and enterobacter spp.* . gynecological infections caused by beta-lactamase producing strains of escherichia coli * , and bacteroides spp.* (including b. fragilis * ). *efficacy for this organism in this organ system was studied in fewer than 10 infections. whi